Taaleri: High unrealised changes in fair values burdened profitability while private asset management performance slightly above our estimates on underlying basis - Nordea
Detta är en aktieanalys producerad av tredje part och reflekterar därför nödvändigtvis ej våra åsikter och värderingar
Taaleri reported Q2 EBIT of EUR 2.4m, coming clearly below Refinitiv consensus at EUR 5.0m. Based on segment reporting, Q2 total income was EUR 11.9m, 13% below Nordea estimate of EUR 13.6m. Recurring revenues were EUR 9.6m in Q2, missing our estimate by 4%. Fair value changes of investments were EUR -7.0m in Q2, while we had anticipated EUR -1.5m.
Investment operations income of EUR 2.3m came below our estimate of EUR 3.5m. Hence, when adjusting for deviation in investment operations, underlying operations EBIT came 30% below our estimate. Private asset management EBIT missed our estimates mainly due to higher costs that can be viewed as one-off in nature. Garantia’s loan losses continued at a low level (-0.2%) while net premiums decreased by 8% y/y, while we had anticipated 8% growth.
Combined ratio was 31.0% in Q2 and beat our estimate of 31.8%. Private asset management AuM was up 4.7% q/q to EUR 2.4bn (EUR 2.2bn in 2021). SolarWind III will be launched in Autumn, while Bio I is expected to start investments in Q3. On initial take, we expect consensus to make slightly negative underlying estimate revision. We have a fair value range of EUR 11.0-12.5 per Taaleri share.
Investment operations income of EUR 2.3m came below our estimate of EUR 3.5m. Hence, when adjusting for deviation in investment operations, underlying operations EBIT came 30% below our estimate. Private asset management EBIT missed our estimates mainly due to higher costs that can be viewed as one-off in nature. Garantia’s loan losses continued at a low level (-0.2%) while net premiums decreased by 8% y/y, while we had anticipated 8% growth.
Combined ratio was 31.0% in Q2 and beat our estimate of 31.8%. Private asset management AuM was up 4.7% q/q to EUR 2.4bn (EUR 2.2bn in 2021). SolarWind III will be launched in Autumn, while Bio I is expected to start investments in Q3. On initial take, we expect consensus to make slightly negative underlying estimate revision. We have a fair value range of EUR 11.0-12.5 per Taaleri share.